|
1) Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005; 106: 3699-709
|
|
|
|
2) Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2009; 113: 6522-7
|
|
|
|
|
|
3) Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 110: 4123-8
|
|
|
|
|
|
4) Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnol. 2007; 25: 1256-64
|
|
|
|
|
|
5) Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009; 373: 759-67
|
|
|
|
|
|
6) Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004; 350: 552-9
|
|
|
|
|
|
7) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355: 1233-43
|
|
|
|
|
|
8) Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008; 111: 1840-7
|
|
|
|
|
|
9) Kanakura Y, Ohyashiki K, Shichishima T, et al. Chronic renal insuficiency in Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH): Improvement with eculizumab treatment in the long-term follow-up of the AEGIS study. Blood. 2009; 114: 783a
|
|
|
|
|
|
10) Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine. 2004; 83: 193-207
|
|
|
|
|
|
11) Hill A, Rother RP, Hillmen P. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Haematologica. 2005; 90 (12 Suppl): ECR40
|
|
|
|
|
|
12) Hill A, Rother RP, Wang X, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010; 149: 414-25
|
|
|
|
|
|
13) Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010; 149: 446-50
|
|
|
|
|
|
14) Danilov AV, Smith H, Craigo S, et al. Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab. Leukemia Res. 2009; 33: e4-5
|
|
|
|
|
|
15) Garty BZ, Ludomirsky A, Danon YL, et al. Placental transfer of immunoglobulin G sub-classes. Clin Diagn Lab Immunol. 1994; 1: 667-9
|
|
|
|
|
|
16) Kelly R, Richards S, Arnold L, et al. A spontaneous reduction of clone size in paroxysmal nocturnal hemoglobinuria patients treated with eculizumab for greater than 12 months. Blood. 2009; 114: 785a
|
|
|
|
|
|
17) Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009; 113: 4094-100
|
|
|
|
|
|
18) Risitano AM, Marando L, Seneca E, et al. Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood. 2008; 112: 449-51
|
|
|
|
|
|
19) Lindorfer MA, Pawluczkowycz AW, Peek EM, et al. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood. 2010; 115: 2283-91
|
|
|
|
|
|
20) Hillmen P. The role of complement inhibition in PNH. Hematology Am Soc Hematol Educ Program. 2008: 116-23
|
|
|
|
|